SCHEMBL2671102

SCHEMBL2671102

COCCNCc1ccc(-c2cc3nccc(Oc4ccc(N(C(=O)C5(C(N)=O)CC5)c5ccc(F)cc5)c(OC)c4)c3s2)nc1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AXL P30530 10/20 0.63
▸ MET P08581 7/20 0.63
▸ KDR P35968 4/20 0.63
▸ FLT3 P36888 3/20 0.63
▸ NTRK1 P04629 2/20 0.63
▸ KIT P10721 2/20 0.63
▸ NTRK2 Q16620 1/20 0.63
▸ MST1R Q04912 9/20 0.52
▸ MERTK Q12866 3/20 0.52
▸ ABL1 P00519 2/20 0.52
▸ LCK P06239 2/20 0.52
▸ LYN P07948 2/20 0.52
▸ HCK P08631 2/20 0.52
▸ BCR P11274 2/20 0.52
▸ SRC P12931 2/20 0.52
▸ ABL2 P42684 2/20 0.52
▸ FRK P42685 2/20 0.52
▸ DDR1 Q08345 2/20 0.52
▸ PTK6 Q13882 2/20 0.52
▸ DDR2 Q16832 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL105538 0.95 MET (0.64) AXLMETKDRFLT3NTRK1
SCHEMBL29514769 0.88 MET (0.73) AXLMETKDRFLT3NTRK1
SCHEMBL103903 0.88 MET (0.73) AXLMETKDRFLT3NTRK1
SCHEMBL104989 0.84 MET (0.67) AXLMETKDRFLT3NTRK1
SCHEMBL10202011 0.83 AXL (0.78) AXLMETKDRFLT3NTRK1
SCHEMBL2534615 0.82 MET (0.65) AXLMETKDRFLT3NTRK1
Malic Acid SCHEMBL29910932 0.82 MET (0.65) AXLMETKDRFLT3NTRK1
Malic Acid SCHEMBL29910999 0.82 MET (0.65) AXLMETKDRFLT3NTRK1
Malic Acid SCHEMBL26110839 0.82 MET (0.65) AXLMETKDRFLT3NTRK1
SCHEMBL2670680 0.82 MET (0.64) AXLMETKDRFLT3NTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2183254-B1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC (CA) 2017-06-21 — — EP disclosed
US-8846927-B2 Inhibitors of protein tyrosine kinase activity METHYLGENE INC. (CA) 2014-09-30 — — US disclosed
US-20130165477-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY METHYLGENE INC. (CA) 2013-06-27 — — US disclosed
US-8389541-B2 Inhibitors of protein tyrosine kinase activity METHYLGENE INC. (CA) 2013-03-05 — — US disclosed
US-20120108628-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY Mirati Therapeutics, Inc. 2012-05-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130165477-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY HGF, ERBB2, MET AXL 130/4885MET 3/4885KDR 11/4885
US-20120108628-A1 INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY HGF, ERBB2, MET AXL 130/4885MET 3/4885KDR 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback